

Søgeprotokol for opdatering på NKR Nationale Kliniske Retningslinjer

Projekttitel/aspekt	Rehabilitering af Prostatakræft – Guidelines 2019
Projektleder	Marie-Louise Kirkegaard Mikkelsen
Fagkonsulent	Anja Ussing
Metodekonsulent	Anja Ussing
Søgespecialist	Kirsten Birkefoss
Senest opdateret	04.08.2019

Baggrund	Fokus for den nationale kliniske retningslinje er foreløbigt afgrænset til mænd med prostatakræft, som efter en faglig vurdering bør tilbydes rehabilitering i forbindelse med nyopstået prostatakræft eller tilbagefald af tidligere prostatakræft og behandling heraf. Den nationale kliniske retningslinje afgrænser sig således fra selve behandlingen af prostatakræft samt terminalpleje og -behandling.
Søgetermer	Engelske: Prostate cancer/s, Prostatic cancer/s, Prostate neoplasm/s, Prostatic neoplasm/s, Prostate tumo(u)r, Prostatic tumo(u)r, Prostate carcinoma/s, Prostatic carcinoma/s, Danske: Prostatakræft, prostatacancer, prostata carcinoma, prostatatumor Norske: Prostatakreft, Prostatacancer, Prostata carcinoma, prostatatumor Svenske: Prostatatumor/tumörer, Prostatakrebs, Prostatacancer
Inklusions- og eksklusionskriterier	Sprog: Engelsk, dansk, norsk og svensk År: 2015 - 2019 Population: Voksne fra og med 18 år Publikationstyper: Guidelines, MTV, Cochrane Reviews

Informationskilder

Databaser	Interface	Fund	Dato for søgning
G-I-N International	http://www.g-i-n.net/	20	03.08.2019
NICE (UK)	http://www.nice.org.uk/	12	03.08.2019
Trip Database	https://www.tripdatabase.com/	31	03.08.2019
Scottish Intercollegiate Guidelines Network (SIGN)	http://sign.ac.uk	0	03.08.2019
HTA Databasen (CRD database)	http://www.crd.york.ac.uk/CRDWeb/	4	03.08.2019
SBU, Sverige	http://www.sbu.se	3	03.08.2019
Socialstyrelsen, Sverige	http://www.socialstyrelsen.se	2	03.08.2019
Hesledirektoratet, Norge	https://helsedirektoratet.no/	1	03.08.2019
FHI, Norge	http://www.fhi.no/	1	03.08.2019
Center for Kliniske Retningslinjer	http://www.cfkr.dk/	0	03.08.2019
NHMRC, Australien	https://www.clinicalguidelines.gov.au/portal/	1	03.08.2019
Canadian Medical Association, Canada	https://joulecma.ca/cpg/homepage	15	03.08.2019
AWMF, Tyskland	http://www.awmf.org/leitlinien/aktuelle-leitlinien.html	1	03.08.2019

Medline	OVID	474	03.08.2019
EMBASE	OVID	608	03.08.2019
CINAHL	EBSCO	294	03.08.2019
PSYCINFO	OVID	10	03.08.2019
PEDRO	http://www.pedro.org.au/	2	03.08.2019

Endvidere er der søgt på hjemmesider for: ASTRO, ESMO, AUA, Cancer Council Australia, Cancer Care Ontario, American Society of Clinical Oncology for nyeste guidelines

Note:

- Guidelines fra firmaet Hayes er fra valgt for denne NKR
- Søgetermer og inklusions- og eksklusionskriterier er tilpasset de enkelte databaser.
- Dubletter er så vidt muligt frasortet ved hjælp af RefWorks. De fundne referencer er overført til Covidence.
- Fuldtekster præsenteres i Covidence i pdf-format eller som link
- Søgestrategi for hver enkelt database præsenteres – hvis muligt vises det eksplicit hvor mange referencer den enkelte søgestreng genererer
- Covidence = webbaseret referencehåndteringssystem og kvalitetsvurderingsværktøj
- MAGIC = online skabelonværktøj til guidelines

SØGESTRATEGI

GIN

Søgt på:

Prostate cancer* OR Prostatic cancer* *OR Prostate neoplas* OR Prostatic neoplas* OR Prostate tumor* OR Prostate tumour* OR Prostatic tumor* OR Prostatic tumour* OR Prostate carcinoma* OR Prostatic carcinoma*

20 fund

Brachytherapy for Patients With Prostate Cancer: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update	ASCO (US) - American Society of Clinical Oncology	Guideline	Mar 27, 2017	United States	Published
Hypofractionated radiotherapy for localized prostate cancer	ASCO (US) - American Society of Clinical Oncology	Guideline	Oct 11, 2018	United States	Published
Magnetic Resonance Imaging for Pre-Treatment Local Staging of Prostate Cancer	McMaster University (CA)	Guideline	Mar 29, 2016	Canada	Published
Optimum imaging strategies for advanced prostate cancer	ASCO (US) - American Society of Clinical Oncology	Guideline	Sep 01, 2019	United States	In development
Prostate cancer: diagnosis and management (NG131)	NICE (UK) - National Institute for Health and Care Excellence	Guideline	May 09, 2019	United Kingdom	Published
Second-Line Hormonal Therapy for Men With Chemotherapy-Naïve, Castration-Resistant Prostate Cancer: American Society of	ASCO (US) - American Society of Clinical Oncology	Guideline	Apr 25, 2017	United States	Published

Clinical Oncology Provisional Clinical Opinion					
Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline	ASCO (US) - American Society of Clinical Oncology	Guideline	Apr 02, 2018	United States	Published
Bone Health and Bone-Targeted Therapies for Prostate Cancer	McMaster University (CA)	Guideline	Sep 23, 2016	Canada	Published
Guideline for Optimization of Surgical and Pathological Quality Performance for Radical Prostatectomy in Prostate Cancer Management	McMaster University (CA)	Guideline	Oct 13, 2017	Canada	Published
Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement	ASCO (US) - American Society of Clinical Oncology	Guideline	Feb 16, 2016	United States	Published
Guidelines for the use of molecular and cellular diagnostics in localized prostate cancer	ASCO (US) - American Society of Clinical Oncology	Guideline	May 01, 2019	United States	In development
Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline	ASTRO (US) - American Society for Radiation Oncology, ASCO (US) - American Society of	Guideline	Oct 11, 2018	United States	Published

	Clinical Oncology				
National klinisk retningslinje for rehabilitering af patienter med prostatakraft [National clinical guidelines for the rehabilitation of patients with prostate cancer]	SST (DK) - Danish Health Authority	Guideline	Sep 08, 2016	Denmark	Published
Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline	ASCO (US) - American Society of Clinical Oncology	Guideline	Sep 05, 2018	United States	Published
Clinical Practice Guidelines for PSA Testing and Early Management of Test-Detected Prostate Cancer	CCA (AU) - Cancer Council Australia	Guideline	Jan 20, 2016	Australia	Published
Guideline for Optimization of Surgical and Pathological Quality Performance for Radical Prostatectomy in Prostate Cancer Management	McMaster University (CA)	Guideline	Oct 13, 2017	Canada	Published
Referral of Suspected Prostate Cancer by Family Physicians and Other Primary Care Providers	McMaster University (CA)	Guideline	Dec 19, 2016	Canada	Published
Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms.	AWMF (DE) - Association of Scientific Medical Societies,	Guideline	Apr 01, 2018	Germany	Published

<p>S3-LL (Leitlinienprogramm Onkologie von AWMF, DKG und DKH) [Interdisciplinary guideline of quality S3 for the early detection, diagnosis and treatment of the various stages of prostate cancer]</p>	<p>DKG (DE) - German Cancer Society</p>				
--	--	--	--	--	--

NICE

Folgt navigation: NICE Guidance > Conditions and Diseases > Cancer > Prostate cancer

1. [Enzalutamide for hormone-relapsed non-metastatic prostate cancer \(TA580\)](#)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published date:
15 May 2019
2. [Prostate cancer: diagnosis and management \(NG131\)](#)
Product type:
Guidance
Programme:
NICE guideline
Published date:
9 May 2019
3. [Padeliporfin for untreated localised prostate cancer \(TA546\)](#)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published date:
21 November 2018
4. [Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer \(IPG590\)](#)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published date:
23 August 2017
5. [Suspected cancer: recognition and referral \(NG12\)](#)
Product type:
Guidance
Programme:
NICE guideline

Last updated:

26 July 2017

Published date:

23 June 2015

6. Irreversible electroporation for treating prostate cancer (IPG572)

Product type:

Guidance

Programme:

Interventional procedures guidance

Published date:

21 December 2016

7. Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA412)

Product type:

Guidance

Programme:

Technology appraisal guidance

Published date:

28 September 2016

8. Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel(TA391)

Product type:

Guidance

Programme:

Technology appraisal guidance

Last updated:

24 August 2016

Published date:

25 May 2016

9. Degarelix for treating advanced hormone-dependent prostate cancer (TA404)

Product type:

Guidance

Programme:

Technology appraisal guidance

Published date:

24 August 2016

10. Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen (TA259)

Product type:

Guidance

Programme:

Technology appraisal guidance

Last updated:

27 July 2016

Published date:

27 June 2012

11. Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA387)

Product type:

Guidance

Programme:

Technology appraisal guidance

Last updated:

27 July 2016

Published date:

27 April 2016

12. [Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated \(TA377\)](#)

Product type:

Guidance

Programme:

Technology appraisal guidance

Published date:

27 January 2016

12 fund

TRIP Database

Søgt på hver af ordene:

Prostate cancer
Prostatic cancer
Prostate neoplasm
Prostatic neoplasm
Prostate tumour
Prostatic tumour
Prostate carcinoma
Prostatic carcinoma

31 fund

1. [Management of locally advanced and metastatic prostate cancer](#)

Management of locally advanced and metastatic prostate cancer Management of locally advanced and metastatic prostatecancer - Cancer Guidelines Wiki Skip Links Personal tools Search Navigation Cancer Council guidelines Methodology Hosted cancer guidelines Adolescents and Young Adult (AYA) guidelines Prevention Policies Social links Page actions Cite this guideline Cancer Council Australia Advanced Prostate Cancer Guidelines Working Party. Management of locally advanced and metastatic prostate (...) cancer. Sydney: Cancer Council Australia. [Version URL: , cited 2019 May 26]. Available from: . Management of locally advanced and metastatic prostate cancer Contents Download Clinical questions: Androgen deprivation therapy (ADT) Radiotherapy Radiotherapy and androgen deprivation therapy (ADT) Surgery Surgery plus androgen deprivation therapy Pathologic T3/T4 disease post radical surgery (Patients with extra capsular extension, seminal vesicle involvement or positive surgical margins) Node-positive

2018 Cancer Council Australia

2. [Clinical practice guidelines PSA Testing and Early Management of Test-Detected Prostate Cancer](#)

Clinical practice guidelines PSA Testing and Early Management of Test-Detected Prostate Cancer Clinical practice guidelines PSA Testing and Early Management of Test-Detected Prostate Cancer - Cancer Guidelines

Wiki Skip Links Personal tools Search Navigation Cancer Council guidelines Methodology
Hosted cancer guidelines Adolescents and Young Adult (AYA) guidelines Prevention Policies Social links Page
actions Cite this guideline Prostate Cancer Foundation of Australia and Cancer Council (...) Australia PSA
Testing Guidelines Expert Advisory Panel. Clinical practice guidelines PSA Testing and Early Management of
Test-Detected Prostate Cancer. Sydney: Cancer Council Australia. [Version URL: , cited 2019 Mar 29].
Available from: . National Health and Medical Research Council These guidelines (recommendations) in the
web-version of this guideline were approved by the Chief Executive Officer of the National Health and
Medical Research Council (NHMRC) on 2 November 2015 under section 14A

2016 Clinical Practice Guidelines Portal

1. [Brachytherapy for Patients with Prostate Cancer: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update](#)

Brachytherapy for Patients with Prostate Cancer: American Society of Clinical Oncology/Cancer Care Ontario
Joint Guideline Update Genitourinary Cancer | ASCO Search form Search ASCO Family of Sites
ASCOconnection.org features blogs from ASCO members, the online version of the membership magazine, a
discussion area, working groups, and links to the ASCO Membership Directory, Career Center, and Volunteer
Portal. ASCO's growing roster of cutting-edge journals serves readers as the most credible (...),
authoritative, peer-reviewed resources for significant clinical oncology research and research that informs
the delivery of efficient, high-quality cancer care across the globe. ASCO Practice Central helps oncology
professionals navigate a complicated and ever-changing practice environment—while providing high-quality
patient care. ASCO University serves as a comprehensive eLearning and mobile learning center that supports
lifelong learning for physicians, advanced practice providers, and patient educators

2017 Cancer Care Ontario

2. [Biodegradable Rectal Spacers for Prostate Cancer Radiotherapy](#)

Biodegradable Rectal Spacers for Prostate Cancer Radiotherapy Recommendation Report 21-5 A Quality
Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) Biodegradable Rectal
Spacers for Prostate Cancer Radiotherapy P Chung, J Brown, D D'Souza, W Koll, S Morgan and the
biodegradable spacer insertion during radiotherapy for prostate cancer recommendation report group
(SPACER RRG) Report Date: January 16, 2019 For information about this document, please contact Dr (...)
Spacers for Prostate Cancer Radiotherapy. Toronto (ON): Cancer Care Ontario: 2019, January 16. Program in
Evidence- based Care Recommendation Report No.: 21-5. Copyright This report is copyrighted
by Cancer Care Ontario; the report and the illustrations herein may not be reproduced without the express
written permission of Cancer Care Ontario. Cancer Care Ontario reserves the right at any time, and at its sole
discretion, to change or revoke this authorization. Disclaimer Care has been taken

2019 Cancer Care Ontario

3. [Guideline for Optimization of Surgical and Pathological Quality Performance for Radical Prostatectomy in Prostate Cancer Management](#)

Guideline for Optimization of Surgical and Pathological Quality Performance for Radical Prostatectomy in Prostate Cancer Management | Cancer Care Ontario Google Tag Manager You are using an outdated browser. We suggest you update your browser for a better experience. for update. Browse Guidelines Browse Pathway Maps Sort by You are here // Guideline for Optimization of Surgical and Pathological Quality Performance for Radical Prostatectomy in Prostate Cancer Management Guidelines & Advice (...)
Guideline for Optimization of Surgical and Pathological Quality Performance for Radical Prostatectomy in Prostate Cancer Management english Version: 2 ID: 17-3 Oct 2017 Type of Content: Guidelines & Advice, Clinical Document Status: Current Authors: J. Chin, J. Srigley, L.A. Mayhew, R.B. Rumble, C. Crossley, A. Hunter, N. Fleshner, B. Bora, R. McLeod, S. McNair, B. Langer, A. Evans, Prostate Cancer Surgery and Pathology Expert Panel Guideline Objective The objective of this document is to provide

2017 Cancer Care Ontario

7. [Follow-Up Model of Care for Cancer Survivors: Recommendations for the Delivery of Follow-up Care for Cancer Survivors in Ontario](#)

visits decreased, the number of primary care visits did not increase during the same time period. This suggests that the primary care-led model can be a cost-effective way to deliver follow-up care for eligible breast cancer survivors. Several Canadian provinces have also implemented the primary care-led follow-up model of care in other cancer survivor populations such as lung, lymphoma, and prostate. 5 Although RCCs have made progress in implementing the new follow-up model of care, provincial data (...) care providers can provide effective surveillance for cancer survivors. Studies in breast, 19,20 colorectal, 21 and prostate 22 cancers showed that when surveillance activities were shifted from specialists to primary care, the clinical (e.g., incidence and rate of recurrence and mortality, time to detection of recurrence) and psychosocial outcomes (e.g., depression, anxiety), and quality of life of survivors were maintained. Survivors also continue to receive surveillance tests that are aligned

2019 Cancer Care Ontario

1. [Prostate cancer: diagnosis and management](#)

Prostate cancer: diagnosis and management Prostate cancer: diagnosis and Prostate cancer: diagnosis and management management NICE guideline Published: 9 May 2019 www.nice.org.uk/guidance/ng131 © NICE 2019. All rights reserved. Subject to Notice of rights (<https://www.nice.org.uk/terms-and-conditions#notice-of-rights>). Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When (...) with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Prostate cancer: diagnosis and management (NG131) © NICE 2019. All rights reserved. Subject to Notice of rights (<https://www.nice.org.uk/terms-and-conditions#notice-of-rights>). Page 2 of 51 Contents Contents Overview 4 Who is it for? 4 Recommendations 5

2. Optimizing Anticancer Therapy in Metastatic Non-castrate Prostate Cancer

Optimizing Anticancer Therapy in Metastatic Non-castrate Prostate Cancer Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline | Journal of Clinical Oncology Search in: Menu Article Tools ASCO SPECIAL ARTICLE Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2018.78.0619 Journal of Clinical Oncology - published online before print April 2, 2018 PMID (...): Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline x Michael J. Morris , x R. Bryan Rumble , x Ethan Basch , x Sebastien J. Hotte , x Andrew Loblaw , x Dana Rathkopf , x Paul Celano , x Rick Bangs , and x Matthew I. Milowsky Michael J. Morris and Dana Rathkopf, Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, New York, NY; R. Bryan Rumble, American Society of Clinical Oncology, Alexandria, VA; Ethan

2018 American Society of Clinical Oncology Guidelines

3. Screening for Prostate Cancer*

Screening for Prostate Cancer* Screening for Prostate Cancer | National Guideline Clearinghouse success fail JUL Aug 12 2018 2019 30 Sep 2016 - 13 Jul 2018 COLLECTED BY Organization: Formed in 2009, the Archive Team (not to be confused with the archive.org Archive-It Team) is a rogue archivist collective dedicated to saving copies of rapidly dying or deleted websites for the sake of history and digital heritage. The group is 100% composed of volunteers and interested parties, and has expanded (...) ? The AHRQ National Guideline Clearinghouse (NGC, guideline.gov) Web site will not be available after July 16, 2018 because federal funding through AHRQ will no longer be available to support the NGC as of that date. For additional information, read our . Guideline Synthesis Screening for Prostate Cancer Guidelines Being Compared: American College of Physicians (ACP) Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians. 2013 Apr

2018 National Guideline Clearinghouse (partial archive)

4. Hypofractionated Radiation Therapy for Localized Prostate Cancer

Hypofractionated Radiation Therapy for Localized Prostate Cancer Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline | Journal of Clinical Oncology Search in: Menu Article Tools ASCO SPECIAL ARTICLE Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.18.01097 Journal of Clinical Oncology - published online before print October 11, 2018 Hypofractionated Radiation Therapy (...) for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline x Scott C. Morgan , x Karen Hoffman , x D. Andrew Loblaw , x Mark K. Buyyounouski , x Caroline Patton , x Daniel Barocas , x Soren Bentzen , x Michael Chang , x Jason Efstathiou , x Patrick Greany , x Per Halvorsen , x Bridget F. Koontz , x Colleen Lawton , x C. Marc Leyrer , x Daniel Lin , x Michael Ray , and x Howard Sandler Scott C. Morgan, The Ottawa Hospital and University of Ottawa, Ottawa; D. Andrew Loblaw, Odette Cancer

5. Early Detection of Prostate Cancer

Early Detection of Prostate Cancer Prostate Cancer: Early Detection Guideline - American Urological Association advertisement Toggle navigation About Us About the AUA Membership AUA Governance Industry Relations Education AUA University Education Products & Resources Normal Histology and Important Histo-anatomic Structures Urinary Bladder Prostate Kidney Renovascular Diseases Adrenal Gland Testis Paratesticular Tumors Penis Retroperitoneum Cytology Online Learning For Medical Students Exams/LLL (...) and Quality of Care Accreditations and Reporting Patient Education Early Detection of Prostate Cancer (2018) Published 2013; Reviewed and Validity Confirmed 2018 The clinical guideline on Early Detection of Prostate Cancer discusses the detection of disease at an early, pre-symptomatic stage through the use of screening tools, such as PSA. Early detection allows for more conservative management, if needed, via means such as active surveillance and watchful waiting. [pdf] Panel Members H. Ballentine Carter

2018 American Urological Association

6. Hypofractionated Radiation Therapy for Localized Prostate Cancer

Hypofractionated Radiation Therapy for Localized Prostate Cancer Prostate Cancer: Hypofractionated Radiotherapy Guideline - American Urological Association advertisement Toggle navigation About Us About the AUA Membership AUA Governance Industry Relations Education AUA University Education Products & Resources Normal Histology and Important Histo-anatomic Structures Urinary Bladder Prostate Kidney Renovascular Diseases Adrenal Gland Testis Paratesticular Tumors Penis Retroperitoneum Cytology (...) Practice Managers' Network (PMN) Patient Safety and Quality of Care Accreditations and Reporting Patient Education Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline (2018) Published 2018 The aim of this guideline is to present recommendations regarding moderately hypofractionated (240-340 cGy per fraction) and ultrahypofractionated (500 cGy or more per fraction) radiation therapy for localized prostate cancer. Panel Members Scott C

2018 American Urological Association

7. Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Cancer Prostate Cancer: Castration Resistant Guideline - American Urological Association advertisement Toggle navigation About Us About the AUA Membership AUA Governance Industry Relations Education AUA University Education Products & Resources Normal Histology and Important Histo-anatomic Structures Urinary Bladder Prostate Kidney Renovascular Diseases Adrenal Gland Testis Paratesticular Tumors Penis Retroperitoneum Cytology Online Learning For Medical Students (...) Patient Safety and Quality of Care Accreditations and Reporting Patient Education Castration-Resistant Prostate Cancer (2018) Published 2013; Amended 2018 Clinicians are challenged with a multitude of treatment options for patients with castration-resistant prostate cancer (CRPC). To assist in clinical decision-making, six index patients were developed representing the most common clinical scenarios that are encountered in clinical practice. With these patients in mind, guideline statements were

8. Hypofractionated Radiation Therapy for Localized Prostate Cancer

Hypofractionated Radiation Therapy for Localized Prostate Cancer Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline | Journal of Clinical Oncology Search in: Menu Article Tools ASCO SPECIAL ARTICLE Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.18.01097 Journal of Clinical Oncology - published online before print October 11, 2018 Hypofractionated Radiation Therapy (...) for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline x Scott C. Morgan , x Karen Hoffman , x D. Andrew Loblaw , x Mark K. Buyyounouski , x Caroline Patton , x Daniel Barocas , x Soren Bentzen , x Michael Chang , x Jason Efstathiou , x Patrick Greany , x Per Halvorsen , x Bridget F. Koontz , x Colleen Lawton , x C. Marc Leyrer , x Daniel Lin , x Michael Ray , and x Howard Sandler Scott C. Morgan, The Ottawa Hospital and University of Ottawa, Ottawa; D. Andrew Loblaw, Odette Cancer

2018 American Society of Clinical Oncology Guidelines

9. Clinically Localized Prostate Cancer

Clinically Localized Prostate Cancer Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline | Journal of Clinical Oncology Search in: Menu Article Tools ASCO SPECIAL ARTICLE Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.18.00606 Journal of Clinical Oncology - published online before print (...) September 5, 2018 PMID: Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline x Justin E. Bekelman , x R. Bryan Rumble , x Ronald C. Chen , x Thomas M. Pisansky , x Antonio Finelli , x Andrew Feifer , x Paul L. Nguyen , x D. Andrew Loblaw , x Scott T. Tagawa , x Silke Gillissen , x Todd M. Morgan , x Glenn Liu , x Neha Vapiwala , x John J. Haluschak , x Andrew

2018 American Society of Clinical Oncology Guidelines

10. ASTRO/AUA Guideline on Hypofractionation for Localized Prostate Cancer

ASTRO/AUA Guideline on Hypofractionation for Localized Prostate Cancer Supplemental Materials for Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO, and AUA Evidence-Based Guideline - Practical Radiation Oncology Email/Username: Password: Remember me Search Terms Search within Search Share this page: Volume 8, Issue 6, Pages 354–360 Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO, and AUA (...) period for guideline), Bayer (Joint Safety Review Committee; ended during disclosure period for guideline); Per Halvorsen: American College of Radiology Radiation Oncology Practice Accreditation program (honoraria, travel expenses); Karen Hoffman: Vanderbilt University (consultant); Patrick Greany: Department of Defense Prostate Cancer Research Program (research funding, honoraria, travel expenses); Bridget Koontz: Janssen (research funding), Blue Earth Diagnostics (advisory board), American Society

11. Prostate Cancer: Screening

Prostate Cancer: Screening Final Update Summary: Prostate Cancer: Screening - US Preventive Services Task Force Search USPSTF Website Text size: Assembly version: 1.0.0.308 Last Build: 11/16/2018 6:27:19 PM You are here: Final Summary Is Prostate Cancer Screening Right For You? (794 KB,) Prostate Cancer: Screening Release Date: May 2018 Recommendation Summary Population Recommendation Grade Men aged 55 to 69 years For men aged 55 to 69 years, the decision to undergo periodic prostate-specific (...) antigen (PSA)–based screening for prostate cancer should be an individual one. Before deciding whether to be screened, men should have an opportunity to discuss the potential benefits and harms of screening with their clinician and to incorporate their values and preferences in the decision. Screening offers a small potential benefit of reducing the chance of death from prostate cancer in some men. However, many men will experience potential harms of screening, including false-positive results

2018 U.S. Preventive Services Task Force

12. Post-treatment Follow-up of Prostate Cancer

Post-treatment Follow-up of Prostate Cancer Revised 2017 ACR Appropriateness Criteria[®] 1 Post-treatment Follow-up of Prostate Cancer American College of Radiology ACR Appropriateness Criteria[®] Post-treatment Follow-up of Prostate Cancer Variant 1: Prostate cancer follow-up. Status post radical prostatectomy. Clinical concern for residual or recurrent disease. Procedure Appropriateness Category Relative Radiation Level C-11 choline PET/CT skull base to mid-thigh Usually Appropriate ??? MRI (...) prostate Usually Not Appropriate O X-ray skeletal survey Usually Not Appropriate ??? ACR Appropriateness Criteria[®] 2 Post-treatment Follow-up of Prostate Cancer Variant 2: Prostate cancer follow-up. Clinical concern for residual or recurrent disease after nonsurgical local and pelvic treatments. Procedure Appropriateness Category Relative Radiation Level C-11 choline PET/CT skull base to mid-thigh Usually Appropriate ??? MRI pelvis without and with IV contrast Usually Appropriate O F-18 fluciclovine

2017 American College of Radiology

13. Clinically localized prostate cancer: AUA/ASTRO/SUO guideline.

Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. | National Guideline Clearinghouse success fail JUN 09 2017 2018 2019 14 Apr 2018 - 12 Jul 2018 COLLECTED BY Organization: Formed in 2009, the Archive Team (not to be confused with the archive.org Archive-It Team) is a rogue archivist collective dedicated to saving copies of rapidly dying or deleted websites for the sake of history and digital heritage. The group is 100 (...) Sign In Username or Email * Password * Remember Me Don't have an account? The AHRQ National Guideline Clearinghouse (NGC, guideline.gov) Web site will not be available after July 16, 2018 because federal funding through AHRQ will no longer be available to support the NGC as of that date. For additional information, read our . Guideline Summary NGC:011220 2017 Apr NEATS Assessment Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. Sanda MG, Chen RC, Crispino T, Freedland S, Greene K

2017 National Guideline Clearinghouse (partial archive)

[15. Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline](#)

Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline Prostate Cancer: Clinically Localized Guideline - American Urological Association advertisement Toggle navigation About Us About the AUA Membership AUA Governance Industry Relations Education AUA University Education Products & Resources Normal Histology and Important Histo-anatomic Structures Urinary Bladder Prostate Kidney Renovascular Diseases Adrenal Gland Testis Paratesticular Tumors Penis Retroperitoneum Cytology Online (...) Managers' Network (PMN) Patient Safety and Quality of Care Accreditations and Reporting Patient Education Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline (2017) Published 2017 These guidelines for the management of localized prostate cancer are structured first, to provide a clinical framework stratified by cancer severity to facilitate care decisions and second, to guide the specifics of implementing the selected management options, including active surveillance, observation/watchful

2017 American Urological Association

[16. Clinically Localized Prostate Cancer Guideline](#)

Clinically Localized Prostate Cancer Guideline 1 Purpose Following a prostate cancer diagnosis, patients are faced with a multitude of care options, the advisability of which is influenced by patient factors and by cancer severity or aggressiveness. The ability to categorize patients based on cancer aggressiveness is invaluable for facilitating care decisions. Accordingly, these guidelines for the management of localized prostate cancer are structured first, to provide a clinical framework (...) stratified by cancer severity (or risk group) to facilitate care decisions and second, to guide the specifics of implementing the selected management options, including active surveillance, observation/watchful waiting, prostatectomy, radiotherapy, cryosurgery, high intensity focused ultrasound (HIFU) and focal therapy. Secondary or salvage treatment for localized prostate cancer that persists or recurs after primary definitive intervention, and primary treatment of locally advanced/metastatic disease

2017 American Society for Radiation Oncology

[17. Second-Line Hormonal Therapy for Men with Chemotherapy-Naïve Castration-Resistant Prostate Cancer PCO](#)

Second-Line Hormonal Therapy for Men with Chemotherapy-Naïve Castration-Resistant Prostate Cancer PCO Second-Line Hormonal Therapy for Men With Chemotherapy-Naïve, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion | Journal of Clinical Oncology Search in: Menu Article Tools ASCO SPECIAL ARTICLE Article Tools OPTIONS & TOOLS COMPANION ARTICLES August, 01 2017 December, 20 2017 ARTICLE CITATION DOI: 10.1200/JCO.2017.72.8030 Journal (...) of Clinical Oncology - published online before print April 25, 2017 PMID: Second-Line Hormonal Therapy for Men With Chemotherapy-Naïve, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion x Katherine S. Virgo , x Ethan Basch , x D. Andrew Loblaw , x Thomas K. Oliver , x R. Bryan Rumble , x Michael A. Carducci , x Luke Nordquist , x Mary-Ellen Taplin , x Eric Winquist , and x Eric A. Singer Katherine S. Virgo, Emory University, Atlanta, GA; Ethan Basch

2017 American Society of Clinical Oncology Guidelines

18. Brachytherapy for Patients With Prostate Cancer

Brachytherapy for Patients With Prostate Cancer Brachytherapy for Patients With Prostate Cancer: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update | Journal of Clinical Oncology Search in: Menu Article Tools ASCO SPECIAL ARTICLE Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2016.72.0466 Journal of Clinical Oncology - published online before print March 27, 2017 PMID: Brachytherapy for Patients (...) With Prostate Cancer: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update x Joseph Chin , x R. Bryan Rumble , x Marisa Kollmeier , x Elisabeth Heath , x Jason Efstathiou , x Tanya Dorff , x Barry Berman , x Andrew Feifer , x Arthur Jacques and x D. Andrew Loblaw Joseph Chin, London Health Sciences Centre, London; Andrew Feifer, Trillium Health Partners' Fidani Cancer Centre, University Health Network, Mississauga; Arthur Jacques, Patient Representative; D. Andrew Loblaw

2017 American Society of Clinical Oncology Guidelines

21. Locally Advanced, High-Risk Prostate Cancer

Locally Advanced, High-Risk Prostate Cancer Date of origin: 1996 Last review date: 2016 ACR Appropriateness Criteria ® 1 Locally Advanced Prostate Cancer American College of Radiology ACR Appropriateness Criteria ® LOCALLY ADVANCED, HIGH-RISK PROSTATE CANCER Expert Panel on Radiation Oncology–Prostate: Patrick W. McLaughlin, MD 1 ; Adam L. Liss, MD 2 ; Paul L. Nguyen, MD 3 ; Dean G. Assimos, MD 4 ; Anthony V. D'Amico, MD, PhD 5 ; Alexander R. Gottschalk, MD, PhD 6 ; Gary S. Gustafson, MD 7 (...); Sameer R Keole, MD 8 ; Stanley L Liauw, MD 9 ; Shane Lloyd, MD 10 ; Benjamin Movsas, MD 11 ; Bradley R Prestidge, MD, MS 12 ; Timothy N. Showalter, MD, MPH 13 ; Al V. Taira, MD 14 ; Neha Vapiwala, MD 15 ; Brian J. Davis, MD, PhD. 16 Summary of Literature Review Introduction/Background Since the previous American College of Radiology (ACR) review of locally advanced, high-risk prostate cancer, a significant policy shift away from screening has been recommended by the US Preventive Services Task Force

2016 American College of Radiology

22. External Beam Radiation Therapy Treatment Planning for Clinically Localized Prostate Cancer

External Beam Radiation Therapy Treatment Planning for Clinically Localized Prostate Cancer Date of origin: 1996 Last review date: 2016 ACR Appropriateness Criteria ® 1 External Beam RT Treatment Planning American College of Radiology ACR Appropriateness Criteria ® EXTERNAL BEAM RADIATION THERAPY TREATMENT PLANNING FOR CLINICALLY LOCALIZED PROSTATE CANCER Expert Panel on Radiation Oncology–Prostate: Nicholas G. Zaorsky, MD 1 ; Timothy N. Showalter, MD, MPH 2 ; Gary A. Ezzell, PhD 3 ; Paul L (...) . Nguyen, MD 4 ; Dean G. Assimos, MD 5 ; Anthony V. D'Amico, MD, PhD 6 ; Alexander R. Gottschalk, MD, PhD 7 ; Gary S. Gustafson, MD 8 ; Sameer R Keole, MD 9 ; Stanley L Liauw, MD 10 ; Shane Lloyd, MD 11 ; Patrick W. McLaughlin, MD 12 ; Benjamin Movsas, MD 13 ; Bradley R Prestidge, MD, MS 14 ; Al V. Taira, MD 15 ; Neha Vapiwala, MD 16 ; Brian J. Davis, MD, PhD. 17 Summary of Literature Review Introduction/Background Prostate cancer is the most common cancer among men in the United States

23. Active Surveillance for the Management of Localized Prostate Cancer Endorsement

Active Surveillance for the Management of Localized Prostate Cancer Endorsement Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement | Journal of Clinical Oncology Search in: Menu Article Tools ASCO SPECIAL ARTICLE Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2015.65.7759 Journal of Clinical Oncology - published (...) online before print February 16, 2016 PMID: Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement x Ronald C. Chen , x R. Bryan Rumble , x D. Andrew Loblaw , x Antonio Finelli , x Behfar Ehdai , x Matthew R. Cooperberg , x Scott C. Morgan , x Scott Tyldesley , x John J. Haluschak , x Winston Tan , x Stewart Justman , x Suneil Jain Ronald C. Chen, University of North Carolina

[Full Text available with Trip Pro](#)

2016 American Society of Clinical Oncology Guidelines

24. Permanent Source Brachytherapy for Prostate Cancer

Permanent Source Brachytherapy for Prostate Cancer American College of Radiology End User License Agreement ACR Appropriateness Criteria is a registered trademark of the American College of Radiology. By accessing the ACR Appropriateness Criteria®, you expressly agree and consent to the terms and conditions as described at: <http://www.acr.org/~media/ACR/Documents/AppCriteria/TermsandConditions.pdf> Personal use of material is permitted for research, scientific and/or information purposes only (...). You may not modify or create derivative works based on American College of Radiology material. No part of any material posted on the American College of Radiology Web site may be copied, downloaded, stored in a retrieval system, or redistributed for any other purpose without the expressed written permission of American College of Radiology. Revised 2016 ACR Appropriateness Criteria® 1 Brachytherapy for Prostate Cancer American College of Radiology ACR Appropriateness Criteria® PERMANENT SOURCE

2016 American College of Radiology

25. Prostate Cancer?Pretreatment Detection, Surveillance, and Staging

Prostate Cancer?Pretreatment Detection, Surveillance, and Staging Revised 2016 ACR Appropriateness Criteria® 1 ProstateCancer–Pretreatment Detection American College of Radiology ACR Appropriateness Criteria® Prostate Cancer–Pretreatment Detection, Surveillance, and Staging Variant 1: Clinically suspected prostate cancer, no prior biopsy (biopsy naïve). Detection. Radiologic Procedure Rating Comments RRL* TRUS guided biopsy prostate 9 O MRI pelvis without and with IV contrast 7 MRI (...) bone scan whole body 1 ??? Rating Scale: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate *Relative Radiation Level Variant 2: Clinically suspected prostate cancer, prior negative TRUS-guided biopsy. Detection. Radiologic Procedure Rating Comments RRL* MRI pelvis without and with IV contrast 8 O MRI targeted biopsy prostate 8 TRUS guided biopsy prostate 7 Repeat TRUS-guided systematic biopsy is a reasonable option, but MRI (with or without contrast) should

2016 American College of Radiology

33. Incontinence after Prostate Treatment: AUA/SUFU Guideline

an economic burden for families and stakeholders. It is a condition that has gained visibility not only due to the extensive use of surgery for prostate cancer but also given to the proliferation of men's continence products available to the lay public. Since IPT is caused by treatment of the prostate, it is, by definition iatrogenic and perhaps preventable or predictable. Understanding the nature of IPT is crucial for patients and practitioners during recovery and extended survivorship. Practitioners (...) and climacturia following prostate cancer surgery ranging from 20-93%, with most reporting an overall rate close to 30%. 35 Such leakage is reported as bothersome by up to half of those patients, and one-third report that they avoid sexual situations due to fear of leakage. 36 The pathophysiology of climacturia is not completely understood. The **mechanism** is thought to relate to removal of the internal sphincter during RP, which is exacerbated by prior transurethral resection of the prostate (TURP). Bladder

2019 American Urological Association

9. Adjuvant and Salvage Radiotherapy after Prostatectomy: ASTRO/AUA Guideline

The purpose of this guideline is to provide direction to clinicians and patients regarding the use of radiotherapy after radical prostatectomy in the adjuvant or salvage setting. The strategies and approaches recommended in the guideline were derived from evidence-based and consensus-based processes. This document constitutes a clinical strategy; therefore, the most effective treatment approach for a particular patient is best determined by the patient, his family, and a multi-disciplinary team of providers using the shared decision-making model. This guideline amendment incorporates newly-published literature into the original ASTRO/AUA Adjuvant and Salvage Radiotherapy after Prostatectomy Guideline and to provide an updated clinical framework for clinicians.

2018 American Society for Radiation Oncology

1. Prostate Cancer

Prostate Cancer Prostate Cancer | Uroweb › Prostate Cancer Prostate Cancer To access the pdfs & translations of individual guidelines, please as EAU member. Non-EAU members can view the web versions. To become an EAU member, click . N. Mottet (Chair), R.C.N. van den Bergh, E. Briers (Patient Representative), P. Cornford (Vice-chair), M. De Santis, S. Fanti, S. Gillissen, J. Grummet, A.M. Henry, T.B. Lam, M.D. Mason, T.H. van der Kwast, H.G. van der Poel, O. Rouvière, D. Tilki, T. Wiegel (...) Guidelines Associates: T. Van den Broeck, M. Cumberbatch, N. Fossati, T. Gross, M. Lardas, M. Liew, L. Moris, I.G. Schoots, P-P.M. Willemse TABLE OF CONTENTS REFERENCES 1. Drost, F.J.H., et al. Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. Cochrane Database of Systematic Reviews, 2019. In press. 2. Van den Broeck, T., et al. Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review

2019 European Association of Urology

2. eUpdate ? Cancer of the Prostate Treatment Recommendations

eUpdate ? Cancer of the Prostate Treatment Recommendations Treatment Recommendations for Cancer of the Prostate | ESMO Welcome to the EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY , the leading European professional organisation for medical oncology. Search Careers at ESMO ESMO Oncology Journals Our journals offer ESMO members and the oncology community a globally visible platform to publish scientific studies, and a highly credible source of educational updates. Connect with ESMO Discover ESMO's new (...) Bronchial and Thymic Tumours • Neuroendocrine Gastroenteropancreatic Tumours • Adrenal Cancer • Thyroid Cancer Gastrointestinal Cancers Rectal Cancer • Biliary cancer • Gastric cancer • Oesophageal cancer • Cancer of the pancreas • Metastatic colorectal cancer • Anal cancer • Early colon cancer • Familial risk colorectal cancer • Hepatocellular carcinoma Genitourinary Cancers Testicular Germ Cell Cancer • Cancer of the Prostate • Bladder Cancer • Renal Cell Carcinoma • Penile Carcinoma • Testicular

2017 European Society for Medical Oncology

SIGN

Søgt på alle emner

0 fund

HTA

Søgt på:

Prostate cancer* OR Prostatic cancer* *OR Prostate neoplas* OR Prostatic neoplas* OR Prostate tumor* OR Prostate tumour* OR Prostatic tumor* OR Prostatic tumour* OR Prostate carcinoma* OR Prostatic carcinoma*

AND

(Project record:ZDT OR Full publication record:ZDT) IN HTA FROM 2016 TO 2019

4 fund (Hayes sorteret fra)

SBU

Søgt på hver af ordene:

Prostatatumor
Prostatatumörer
Prostatakrebs
Prostatacancer

3 fund

Bilddiagnostik vid stadieindelning av prostatacancer

Lästid ca 4 minuter Publicerad 2014-09-09 Publikationer: SBU Utvärderar

SBU, Statens beredning för medicinsk och social utvärdering, har i uppdrag att utvärdera metoder och insatser som används i hälso- och sjukvården och socialtjänsten.

Bilddiagnostik vid misstänkt prostatacancer

Lästid ca 4 minuter Publicerad 2014-02-05 Publikationer: SBU Utvärderar

Systematisk litteraturoversikt som granskar diagnostikmetoder, magnetkameraundersökning, positronemissionstomografi med datortomografi, ultraljud med Doppler, ultraljudsteknik, elastografi, **Tilläggsmetoder till PSA-test för diagnostik av prostatacancer**

Publicerad 2018-02-12

I denna rapport redovisas det vetenskapliga underlaget som tagits fram till Socialstyrelsen avseende olika metoders träffsäkerhet att diagnostisera prostatacancer hos män med ett PSA-värde mellan 1

Socialstyrelsen

Søgt på hver af ordene:

Prostatatumor
Prostatatumörer
Prostatakrebs
Prostatacancer

0 fund

Helsedirektoratet

Søgt på hver af ordene:

Prostatakraft, Prostatacancer, Prostata carcinoma, Prostatatumor, Prostatatumorer

0 fund

FHI (Folkehelseinstituttet)

Søgt på hvert af ordene:

Prostatakraft, Prostatacancer, Prostata carcinoma, Prostatatumor, Prostatatumorer

2 fund

Metodevurdering for fire legemidler for pasienter med metastaserende kastrasjonsresistent prostatakraft

I denne metodevurderingen har vi sammenlignet klinisk effekt og kostnadseffektivitet av fire legemidler som brukes for pasienter med metastatisk kastrasjonsresistent prostatakraft. Legemidlene er abirateron, kabazitaxel, enzalutamid og radium-223.

METODEVURDERING

Publisert 30.08.2016 Oppdatert 15.12.2016

Effekt av fysisk trening for personer med kreft

- **Utgitt:** Juni 2016
 - **Av:** Folkehelseinstituttet
 - **Forfattere:** Dahm KT, Larun L, Kirkehei I, Reinart LM.
 - **ISBN ELEKTRONISK:** 978-82-8082-724-1
-

Center for Kliniske Retningslinjer

Søgt gennem alle retningslinjer

0 fund

NHMRC, Australien

Søgt på hver af ordene:

Prostate cancer
Prostatic cancer
Prostate neoplasm
Prostatic neoplasm
Prostate tumour
Prostatic tumour
Prostate carcinoma
Prostatic carcinoma

1 fund

Canadian Medical Association, Canada

Søgt på hver af ordene:

Prostate cancer
Prostatic cancer
Prostate neoplasm

Prostatic neoplasm
Prostate tumour
Prostatic tumour
Prostate carcinoma
Prostatic carcinoma

15 fund

1. Canadian Urological Association recommendations on prostate cancer screening and early diagnosis

Canadian Urological Association

Published on: 2017-11

[Details](#)

[- Remove from the Clipboard](#)

2. Bone health and bone-targeted therapies for prostate cancer

Cancer Care Ontario's Program in Evidence-based Care

Published on: 2016-09

[Details](#)

[- Remove from the Clipboard](#)

3. Referral of suspected prostate cancer by family physicians and other primary care providers

Cancer Care Ontario's Program in Evidence-based Care

Published on: 2016-12

[Details](#)

[- Remove from the Clipboard](#)

4. Models of care for cancer survivorship

Cancer Care Ontario's Program in Evidence-based Care

Published on: 2017-03

[Details](#)

[- Remove from the Clipboard](#)

5. Follow-up care and psychosocial needs of survivors of prostate cancer

Cancer Care Ontario's Program in Evidence-based Care

Published on: 2015-06

[Details](#)

[- Remove from the Clipboard](#)

6. Multiparametric magnetic resonance imaging for pre-treatment local staging of prostate cancer: a Cancer Care Ontario clinical practice guideline

Cancer Care Ontario's Program in Evidence-based Care

Published on: 2016-09

[Details](#)

[- Remove from the Clipboard](#)

7. Follow-up care for survivors of prostate cancer - clinical management: a Program in Evidence-Based Care systematic review and clinical practice guideline

Cancer Care Ontario's Program in Evidence-based Care

Published on: 2017-09

[Details](#)

[- Remove from the Clipboard](#)

8. Cancer Care Ontario position statement on prostate cancer screening using the prostate-specific antigen (PSA) test

Cancer Care Ontario's Program in Evidence-based Care

Published on: 2017-04

[Details](#)

[- Remove from the Clipboard](#)

9. Evidence-based guideline recommendations on multiparametric magnetic resonance imaging in the diagnosis of prostate cancer: a Cancer Care Ontario clinical practice guideline

Cancer Care Ontario's Program in Evidence-based Care

Published on: 2017-01

[Details](#)

[- Remove from the Clipboard](#)

10. Guideline for optimization of surgical and pathological quality performance for radical prostatectomy in prostate cancer management

Cancer Care Ontario's Program in Evidence-based Care

Published on: 2017-10

[Details](#)

[- Remove from the Clipboard](#)

11. Performance of needle biopsy of the prostate for men with suspected or established prostate cancer

Cancer Care Ontario's Program in Evidence-based Care

Published on: 2017-09

[Details](#)

[- Remove from the Clipboard](#)

12. Biodegradable rectal spacers for prostate cancer radiotherapy

Cancer Care Ontario's Program in Evidence-based Care

Published on: 2019-01

[Details](#)

[- Remove from the Clipboard](#)

13. Local prostate cancer

Alberta Health Services - Cancer Care

Published on: 2017-01

[Details](#)

[- Remove from the Clipboard](#)

14. Brachytherapy for patients with prostate cancer: American Society of Clinical Oncology/cancer care Ontario joint guideline update

American Society of Clinical Oncology
Cancer Care Ontario's Program in Evidence-based Care

Published on: 2017-03

[Details](#)

[- Remove from the Clipboard](#)

15. Prostate cancer

Alberta Health Services - Cancer Care

Published on: 2015-03

[Details](#)

[- Remove from the Clipboard](#)

AWMF, Tyskland

Søgt på hver af ordene:

Prostatakarzinom

Prostatakrebs

1 fund

Medline

474 fund

Database(s): **Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Daily and Versions(R)** 1946 to August 02, 2019

Search Strategy:

#	Searches	Results
1	exp Prostatic neoplasm/	121838
2	((prostatic or prostate) adj2 (cancer* or neoplas* or tumo?r* or carcinoma* or oncolog*)).ti,kw,kf.	90451
3	((prostatic or prostate) and (cancer* or neoplas* or tumo?r* or carcinoma* or oncolog*)).ab. and ((cancer* or neoplas* or tumo?r* or carcinoma* or oncolog*) and survivor*).ti,kw.	705
4	or/1-3	136098
5	limit 4 to (guideline or practice guideline)	266
6	(Guideline* or practice guideline* or clinical guideline* or guidance or recommendations).ti,kw,kf.	123080
7	(cochrane or health technology).jw.	14374
8	(hta or health technology assessment*).ti,ab,kw,kf.	
9	or/6-8	137435
10	4 and 9	1152
11	5 or 10	1242
12	limit 11 to (yr="2015-2019" and (danish or english or german or norwegian or swedish))	474

Embase

608 fund

Database(s): **Embase** 1974 to 2019 August 02

Search Strategy:

#	Searches	Results
1	exp Prostate tumor/ or exp Prostate cancer/	228243
2	((prostatic or prostate) adj2 (cancer* or neoplasm* or tumo?* or carcinoma* or oncolog*)).ti,kw.	134663
3	((prostatic or prostate) and (cancer* or neoplas* or tumo?* or carcinoma* or oncolog*)).ab. and ((cancer* or neoplas* or tumo?* or carcinoma* or oncolog*) and survivor*).ti,kw.	913
4	or/1-3	235018
5	(Guideline* or practice guideline* or clinical guideline* or guidance or hta or health technology assessment*).ti,kw,pt.	138406
6	(Cochrane or health technology).jx.	20332
7	or/5-6	
8	4 and 7	1623
9	limit 8 to (yr="2015-2019" and (danish or english or german or norwegian or swedish))	608

PsycInfo

10 fund

Database(s): **PsycINFO** 1806 to July Week 5 2019

Search Strategy:

#	Searches	Results
1	((prostatic or prostate) adj2 (cancer* or neoplasm* or tumo?* or carcinoma* or oncolog*)).ti,id.	2101
2	((prostatic or prostate) adj2 (cancer* or neoplas* or tumo?* or carcinoma* or oncolog*)).ab. and ((cancer* or neoplas* or tumo?* or carcinoma* or oncolog*) and survivor*).ti,id.	250
3	or/1-2	2173
4	Treatment guidelines/	6467
5	(Guideline or guidelines or practice guideline or practice guidelines or treatment guideline or treatment guidelines or clinical guideline or clinical guidelines or guidance or recommendations).ti,id.	41542
6	or/4-5	43306
7	3 and 6	36
8	limit 7 to (yr="2015-2019" and (danish or english or german or norwegian or swedish))	10

Cinahl

294 fund

#	Query	Limiters/Expanders	Results
S8	S4 AND S7	Limiters - Published Date: 20151001-20190831; Language: Danish, English, German, Norwegian, Swedish	294
S7	S5 OR S6		116,416
S6	TI (Guideline* or guidance or recommendations) OR SU (Guideline* or guidance or recommendations)		112,636
S5	PT practice guidelines or MH practice guidelines		75,822
S4	S1 OR S2 OR S3		32,785
S3	(AB (prostatic or prostate) N2 (cancer* or neoplas* or tumo#r* or carcinoma* or oncolog*)) and (TI ((cancer* or neoplas* or tumo?r* or carcinoma* or oncolog*) and survivor*) OR SU ((cancer* or neoplas* or tumo?r* or carcinoma* or oncolog*) and survivor*))		498
S2	((prostatic or prostate) N2 (cancer* or neoplas* or tumo#r* or carcinoma* or oncolog*))		32,785
S1	(MH "Prostatic Neoplasms+")		26,169

PEDRO

Søgt på hvert ord:

Prostate cancer
Prostatic cancer*
Prostate neoplasm
Prostatic neoplasm*
Prostate tumour
Prostatic tumour*
Prostatic tumor
Prostate tumor*
Prostate carcinoma
Prostatic carcinoma*

AND

Method: Practice guideline Published since: 2015

2 fund
